Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Refining Tumor Mutational Burden as a Predictive Biomarker for Pembrolizumab: A Real-World Analysis in Japanese Patients.

Cancer science - 1 Apr 2026

Yasuda Tomoyo, Yumura Mio, Hamasaki Azusa, Fei Tongyi, Kubo Takashi, Ichikawa Hitoshi, Kohno Takashi, Sunami Kuniko

Abstract excerpt

Tumor mutational burden (TMB) is a key biomarker for predicting the response to immune checkpoint inhibitors (ICIs). However, its predictive accuracy in real-world clinical practice, particularly in Asian populations, remains inadequately evaluated. We addressed this issue by analyzing real-world data from 63,952 patients registered in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to Biomarkers, Tumor

Share to East Asian People

Share to Neoplasms

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 41614225
DOI: 10.1111/cas.70331
PMCID: PMC13045439

Genes

CAT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Refining Tumor Mutational Burden as a Predictive Biomarker for Pembrolizumab: A Real-World Analysis in Japanese Patients.PMID 41614225Read ↗

Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab.Semantic proximity Read ↗

Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.Semantic proximity Read ↗

Designing gene panels for tumor mutational burden estimation: the need to shift from ‘correlation’ to ‘accuracy’Semantic proximity Read ↗

Expert consensus on the detection and clinical application of tumor mutational burden.Semantic proximity Read ↗

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent mannerSemantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker in Solid TumorsSemantic proximity Read ↗

Interplay between Tumor Mutational Burden and Mutational Profile and its effect on overall survival: A Post Hoc Analysis of Metastatic Patients Treated with Immune Checkpoint InhibitorsSemantic proximity Read ↗

Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities.Semantic proximity Read ↗

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.Semantic proximity Read ↗

Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-makingSemantic proximity Read ↗

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkersSemantic proximity Read ↗

Tumor Mutational Load: A Novel Predictor for Clinical Benefit of Pembrolizumab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.